Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to cut unnecessary pills for dementia patients

NCT ID NCT04938648

Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a program where a pharmacist worked with people living with dementia, their care partners, and their doctors to review and reduce unnecessary medications. The goal was to simplify medication routines and lower treatment burden. The study included 138 participants aged 65 and older with dementia and multiple chronic conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacist-led deprescribing intervention (educational materials, telehealth visit, and provider communication)
What this could lead to
If successful, this approach could help people with dementia take fewer unnecessary medications, reducing side effects and simplifying daily care.
What could go wrong
This is a small feasibility study, not a large trial. The program may not work for everyone, and deprescribing must be done carefully to avoid withdrawal risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

138 people

The number who actually took part.

Started

Jun 2021

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 65 or greater * Diagnosis of dementia from International Classification of Diseases (ICD) -9 or ICD-10 codes * At least one other chronic condition * Five or more chronic medications (to include all prescription and over-the-counter medications, both scheduled and as needed) * Have a primary care physician at the pilot clinic who has enrolled in the study; this will be defined as having had at least 1 previous visit with that physician Care partners: \- Family or other companions age 21 years or greater who regularly help the patient with managing medications Exclusion Criteria: * As both the pilot and the planned pragmatic trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded. * Individuals who cannot converse comfortably in English will be excluded because the FCMAHS has not been validated in other languages.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease and related dementias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease and related dementias Polypharmacy

Contacts and locations

Locations

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224, United States

  • Kaiser Permanente

    Aurora, Colorado, 80014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.